Canopy Growth (CGC) versus Pharmacyte Biotech (PMCB) Financial Survey

Canopy Growth (NYSE:CGC) and Pharmacyte Biotech (OTCMKTS:PMCB) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Canopy Growth and Pharmacyte Biotech, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Canopy Growth 1 1 2 0 2.25
Pharmacyte Biotech 0 0 0 0 N/A

Canopy Growth presently has a consensus price target of $36.67, indicating a potential upside of 20.85%. Given Canopy Growth’s higher probable upside, equities analysts plainly believe Canopy Growth is more favorable than Pharmacyte Biotech.

Profitability

This table compares Canopy Growth and Pharmacyte Biotech’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Canopy Growth -503.14% -26.32% -18.43%
Pharmacyte Biotech N/A -101.19% -90.40%

Risk & Volatility

Canopy Growth has a beta of 3.55, suggesting that its stock price is 255% more volatile than the S&P 500. Comparatively, Pharmacyte Biotech has a beta of 2.26, suggesting that its stock price is 126% more volatile than the S&P 500.

Earnings & Valuation

This table compares Canopy Growth and Pharmacyte Biotech’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Canopy Growth $60.79 million 115.87 -$54.88 million ($0.32) -94.81
Pharmacyte Biotech N/A N/A -$6.82 million N/A N/A

Pharmacyte Biotech has lower revenue, but higher earnings than Canopy Growth.

Insider & Institutional Ownership

12.0% of Canopy Growth shares are owned by institutional investors. Comparatively, 0.1% of Pharmacyte Biotech shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Canopy Growth beats Pharmacyte Biotech on 7 of the 9 factors compared between the two stocks.

About Canopy Growth

Canopy Growth Corporation, together with its subsidiaries, engages in growing, possession, and sale of medical cannabis in Canada. Its products include dried flowers, oils and concentrates, softgel capsules, and hemps. The company offers its products under the Tweed, Black Label, Spectrum Cannabis, DNA Genetics, Leafs By Snoop, Bedrocan Canada, CraftGrow, and Foria brand names. It also offers its products through Tweed Main Street, a single online platform that enables registered patients to purchase medicinal cannabis from various producers across various brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.

About Pharmacyte Biotech

PharmaCyte Biotech, Inc., a clinical stage biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of the cancer. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and therapies for cancer based on the constituents of the Cannabis plant. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was founded in 1996 and is based in Laguna Hills, California.

Receive News & Ratings for Canopy Growth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Canopy Growth and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply